Double targeted constructs to affect tumor kill
The present technology is directed to compounds, compositions, medicaments, and methods related to the treatment of cancers expressing PSMA. The compounds are of Formulas I & II or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer.
1. A compound of Formula I
or a pharmaceutically acceptable salt thereof, wherein
X 1 is 124 I, 125 I, 127 I, 131 I, 211 At or Sn(R 4 ) 3 ;
R 1 , R 2 , and R 3 are each independently H, methyl, benzyl, 4-methoxybenzyl, or tert-butyl;
R 4 is independently at each occurrence an alkyl group;
n is 1 or 2; and
m is 1, 2, or 3.
2. The compound of claim 1 , wherein when n is 2, then m is not 2.
3. The compound of claim 1 , wherein X 1 is 124 I, 125 I, 131 I, or 211 At.
4. The compound of claim 3 , wherein R 5 , R 6 , and R 7 are each independently H.
5. The compound of claim 1 , wherein the compound of Formula I is a compound of Formula Ia
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 5 , wherein X 2 is 124 I, 125 I, 131 I, or 211 At and wherein R 5 , R 6 , and R 7 are each independently H.
7. The compound of claim 6 , wherein X 2 is 211 At.
8. A composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.
9. A composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier.
10. A composition comprising a compound of claim 6 and a pharmaceutically acceptable carrier.
11. A pharmaceutical composition for treating a cancer expressing prostate specific membrane antigen (“PSMA”), the composition comprising an effective amount of the compound of claim 3 for treating the cancer and a pharmaceutically acceptable excipient wherein the cancer is non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, or prostate cancer.
12. A pharmaceutical composition for treating a cancer expressing prostate specific membrane antigen (“PSMA”), the composition comprising an effective amount of the compound of claim 4 for treating the cancer and a pharmaceutically acceptable excipient wherein the cancer is non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, or prostate cancer.
13. A pharmaceutical composition for treating a cancer expressing prostate specific membrane antigen (“PSMA”), the composition comprising an effective amount of the compound of claim 6 for treating the cancer and a pharmaceutically acceptable excipient wherein the cancer is non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, or prostate cancer.
14. A method comprising administering an effective amount of a compound of claim 3 to a subject suffering from non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, or prostate cancer.
15. The method of claim 14 , wherein administering the compound comprises parenteral administration.
16. A method comprising administering an effective amount of a compound of claim 4 to a subject suffering from non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, or prostate cancer.
17. The method of claim 16 , wherein administering the compound comprises parenteral administration.
18. A method comprising administering an effective amount of a compound of claim 6 to a subject suffering from non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, or prostate cancer.
19. The method of claim 18 , wherein administering the compound comprises parenteral administration.